The French Microbiome company completed its first clinical study proving that Autologous Fecal Microbiota Transfer induced a 90% recovery of…
Categorie
2017
Maat Pharma has reached the target number of patients to be treated in its first clinical trial, Odyssée.
July 20, 2017
Lyon (France), June 15, 2017. A few days after signing a strategic partnership for the treatment of intestinal dysbiosis by…
June 15, 2017
MaaT Pharma’s disruptive business model: exponential growth.
June 8, 2017
MaaT Pharma and BIOASTER just entered into an agreement to investigate the potentiality to expand fecal microbiota in vitro.
February 16, 2017
We are a clinical-stage microbiome therapeutics company aiming to improve survival in cancer.
Ressources
Contact
Nous sommes une société au stade clinique, spécialisée dans les thérapies issues du microbiote dédiées aux patients atteints de cancer.
Contact
Nous sommes une société au stade clinique, spécialisée dans les thérapies issues du microbiote dédiées aux patients atteints de cancer.